These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

266 related articles for article (PubMed ID: 22560500)

  • 21. The relation between α-synuclein and microglia in Parkinson's disease: Recent developments.
    Sanchez-Guajardo V; Tentillier N; Romero-Ramos M
    Neuroscience; 2015 Aug; 302():47-58. PubMed ID: 25684748
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Alpha-synuclein pathology in Parkinson's and Alzheimer's disease brain: incidence and topographic distribution--a pilot study.
    Jellinger KA
    Acta Neuropathol; 2003 Sep; 106(3):191-201. PubMed ID: 12845452
    [TBL] [Abstract][Full Text] [Related]  

  • 23. α-Synuclein mRNA and soluble α-synuclein protein levels in post-mortem brain from patients with Parkinson's disease, dementia with Lewy bodies, and Alzheimer's disease.
    Quinn JG; Coulson DT; Brockbank S; Beyer N; Ravid R; Hellemans J; Irvine GB; Johnston JA
    Brain Res; 2012 Jun; 1459():71-80. PubMed ID: 22560502
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Aggregation of alpha-synuclein in the pathogenesis of Parkinson's disease.
    Iwatsubo T
    J Neurol; 2003 Oct; 250 Suppl 3():III11-4. PubMed ID: 14579119
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Generation of a alpha-synuclein-based rat model of Parkinson's disease.
    Recchia A; Rota D; Debetto P; Peroni D; Guidolin D; Negro A; Skaper SD; Giusti P
    Neurobiol Dis; 2008 Apr; 30(1):8-18. PubMed ID: 18313315
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Interactions Between α-Synuclein and Tau Protein: Implications to Neurodegenerative Disorders.
    Li X; James S; Lei P
    J Mol Neurosci; 2016 Nov; 60(3):298-304. PubMed ID: 27629562
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Alpha-synuclein: Pathology, mitochondrial dysfunction and neuroinflammation in Parkinson's disease.
    Rocha EM; De Miranda B; Sanders LH
    Neurobiol Dis; 2018 Jan; 109(Pt B):249-257. PubMed ID: 28400134
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Oxidative and nitrative alpha-synuclein modifications and proteostatic stress: implications for disease mechanisms and interventions in synucleinopathies.
    Schildknecht S; Gerding HR; Karreman C; Drescher M; Lashuel HA; Outeiro TF; Di Monte DA; Leist M
    J Neurochem; 2013 May; 125(4):491-511. PubMed ID: 23452040
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Protein array analysis of oligomerization-induced changes in alpha-synuclein protein-protein interactions points to an interference with Cdc42 effector proteins.
    Schnack C; Danzer KM; Hengerer B; Gillardon F
    Neuroscience; 2008 Jul; 154(4):1450-7. PubMed ID: 18541383
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Endoplasmic reticulum stress and mitochondrial cell death pathways mediate A53T mutant alpha-synuclein-induced toxicity.
    Smith WW; Jiang H; Pei Z; Tanaka Y; Morita H; Sawa A; Dawson VL; Dawson TM; Ross CA
    Hum Mol Genet; 2005 Dec; 14(24):3801-11. PubMed ID: 16239241
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Review: Parkinson's disease: from synaptic loss to connectome dysfunction.
    Bellucci A; Mercuri NB; Venneri A; Faustini G; Longhena F; Pizzi M; Missale C; Spano P
    Neuropathol Appl Neurobiol; 2016 Feb; 42(1):77-94. PubMed ID: 26613567
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Nigral burden of alpha-synuclein correlates with striatal dopamine deficit.
    Kovacs GG; Milenkovic IJ; Preusser M; Budka H
    Mov Disord; 2008 Aug; 23(11):1608-12. PubMed ID: 18649394
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Age-associated increases of alpha-synuclein in monkeys and humans are associated with nigrostriatal dopamine depletion: Is this the target for Parkinson's disease?
    Chu Y; Kordower JH
    Neurobiol Dis; 2007 Jan; 25(1):134-49. PubMed ID: 17055279
    [TBL] [Abstract][Full Text] [Related]  

  • 34. The pathomechanisms underlying Parkinson's disease.
    Jellinger KA
    Expert Rev Neurother; 2014 Feb; 14(2):199-215. PubMed ID: 24471711
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Wild-type and mutant alpha-synuclein induce a multi-component gene expression profile consistent with shared pathophysiology in different transgenic mouse models of PD.
    Miller RM; Kiser GL; Kaysser-Kranich T; Casaceli C; Colla E; Lee MK; Palaniappan C; Federoff HJ
    Exp Neurol; 2007 Mar; 204(1):421-32. PubMed ID: 17254569
    [TBL] [Abstract][Full Text] [Related]  

  • 36. The role of α-synuclein in neurotransmission and synaptic plasticity.
    Cheng F; Vivacqua G; Yu S
    J Chem Neuroanat; 2011 Dec; 42(4):242-8. PubMed ID: 21167933
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Viral vector-mediated overexpression of α-synuclein as a progressive model of Parkinson's disease.
    Ulusoy A; Decressac M; Kirik D; Björklund A
    Prog Brain Res; 2010; 184():89-111. PubMed ID: 20887871
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Targeting intracellular and extracellular alpha-synuclein as a therapeutic strategy in Parkinson's disease and other synucleinopathies.
    Vekrellis K; Stefanis L
    Expert Opin Ther Targets; 2012 Apr; 16(4):421-32. PubMed ID: 22480256
    [TBL] [Abstract][Full Text] [Related]  

  • 39. alpha-Synuclein at the synaptic gate.
    Surmeier DJ
    Neuron; 2010 Jan; 65(1):3-4. PubMed ID: 20152107
    [TBL] [Abstract][Full Text] [Related]  

  • 40. A new role for α-synuclein in Parkinson's disease: Alteration of ER-mitochondrial communication.
    Guardia-Laguarta C; Area-Gomez E; Schon EA; Przedborski S
    Mov Disord; 2015 Jul; 30(8):1026-33. PubMed ID: 25952565
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 14.